Loading
Old version — revision 3
This is a fixed snapshot of Buck Institute for Research on Aging, saved by Import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Re-import of content/buck-institute.md — the file changed after the initial import. Not an edit.
Read the current versionWhat this revision changedAll 3 revisions
An independent research institute in Novato, California, opened in 1999 as the first in the world dedicated solely to the biology of aging.
Buck Institute for Research on Aging is an independent, nonprofit biomedical research institute in Novato, California, opened in 1999 and the first research organization in the world dedicated exclusively to the biology of aging. It is central to the modern geroscience programme both intellectually and institutionally. Much of the foundational work on Cellular senescence and the senescence-associated secretory phenotype was done there, and a substantial share of the field's principal investigators and company founders trained in its laboratories.
The institute is organized around the geroscience premise, which holds that the major chronic diseases of later life share upstream biological drivers and that intervening on those drivers would do more good than treating each disease separately. Its research is organized around aging mechanisms rather than around organ systems or diseases, which is unusual for a biomedical institute and was more unusual still when it opened.
The institute lists 26 faculty and research professors,1 alongside a graduate programme and a translational arm intended to move findings toward companies. Its scale is modest relative to Calico Life Sciences or Altos Labs: its federal filings report expenses of roughly $63 million in the fiscal year ending June 2025, against revenue of $57 million.2 Its output per dollar has been correspondingly high.
The institute owes its existence to a lawsuit. Leonard and Beryl Buck left a charitable trust for use in Marin County, California, and the trust's assets grew far beyond expectation after the value of its holdings rose. Litigation in the 1980s over whether the money had to be spent within one wealthy county ended in a settlement that funded several new institutions, among them a research centre on aging.
Construction on a campus designed by I. M. Pei began in the 1990s, and the institute opened in 1999. Dale Bredesen was its founding president. Brian Kennedy, a yeast geneticist known for work on the genetics of lifespan, led it during the first half of the 2010s, and Eric Verdin, an immunologist and metabolism researcher, has been president and chief executive since late 2016, with the autophagy researcher Malene Hansen serving as chief scientific officer.1
The institute's most consequential contribution is the biology of senescent cells. Judith Campisi, who worked at the Buck from its early years until her death in 2024, established that senescent cells are metabolically active as well as arrested, secreting a complex mixture of cytokines, proteases and growth factors now called the senescence-associated secretory phenotype.3 The finding turned senescence from a cell-culture curiosity into a mechanism by which a small number of cells could drive tissue-wide dysfunction, and it is the direct intellectual ancestor of Senolytics as a drug class.
Campisi also articulated the antagonistic-pleiotropy account of senescence. The programme suppresses cancer in young animals by arresting damaged cells and harms old ones through the same secretory activity, an evolutionary tradeoff rather than a design flaw.4 The proof that this matters causally came from elsewhere, when a Mayo Clinic group showed that genetically clearing p16-positive cells delayed several age-associated pathologies in mice,5 but the mechanistic account that made the experiment interpretable was largely built at the Buck. It also connects senescence directly to Inflammaging, since the secretory phenotype is one of the principal sources of the chronic sterile inflammation that characterizes aged tissue.
Several laboratories work on Autophagy and the mechanisms of Proteostasis collapse failure, including their role in neurodegeneration. The work connects directly to the observation that most interventions extending lifespan in model organisms require an intact autophagy pathway.
Work on ketone bodies, NAD metabolism and dietary interventions links the institute to the Caloric restriction literature and to the pharmacology of Rapamycin and NAD+ precursors. Verdin's own research concerns sirtuins and the metabolic control of gene expression.
Alongside mouse studies, the institute maintains substantial invertebrate work, including C. elegans and Drosophila screens for compounds and genes affecting lifespan. It also contributes to the Aging biomarkers effort that the field needs before any intervention can be tested efficiently in humans. Invertebrate screens are cheap and fast. They are also the reason the field has a long list of compounds that extend lifespan in worms and almost none that have done anything measurable in a person, a filtering problem that the Epigenetic clocks literature has not solved either.
Why an independent instituteAging research is poorly served by disease-oriented funding, because no funding agency has a study section for a process that is not a disease. An institute organized around mechanisms rather than organs can support work that would fall between the cracks of a university's departmental structure. The Buck's founders made that argument, and the SENS Research Foundation later made it in a different register.
The institute is funded by a combination of the original endowment, competitive federal grants (principally from the National Institute on Aging), philanthropy, and industry collaboration. Its filings for the fiscal year ending June 2025 report contributions and grants as the large majority of revenue.2 It is not a university and grants no undergraduate degrees, but it operates a doctoral programme in the biology of aging in partnership with the University of Southern California, one of very few graduate programmes anywhere organized around the subject.
That programme is the institute's second major contribution. Aging biology had no training pipeline of its own until relatively recently, and researchers entered it laterally from cancer biology, genetics or metabolism. A dedicated programme trains people to frame their questions in the field's own terms from the start.
The Buck's position is unusual. Mainstream biology respects it in a way it does not respect most institutions associated with life extension, and parts of the longevity advocacy community treat it with suspicion for the same reason. Its researchers publish in conventional venues, avoid claims about lifespan extension in humans, and have been publicly critical of the field's commercial overreach.
Its spin-outs and alumni are widely distributed. Unity Biotechnology, founded on senescence biology with Campisi among its scientific founders, ran some of the earliest clinical trials of senolytic drugs. Their results were largely negative, and the institute's researchers have discussed that openly rather than minimizing it. Other alumni run laboratories and companies across the sector, and the institute's people appear on the advisory boards of most large longevity ventures, including as consultants to the well-funded reprogramming companies.
The main criticism directed at the institute applies to the whole field. A quarter-century of well-regarded mechanistic work on aging has produced no approved intervention against aging in humans, and the institute's own scientists are among those who point out that the gap between mouse and human results has not narrowed.
In the near term, the institute depends on the same thing as the whole field: whether a validated measure of biological aging can be qualified as an endpoint, which would make aging-directed trials affordable. The Buck contributes to that effort and would be a principal beneficiary of success.
A second question concerns the field's centre of gravity. When the institute opened, it was the only place doing this work at scale; as of 2026 several private companies have larger budgets and can pay more. Its next decade will show whether an independent academic institute keeps a distinctive role in that environment, as a trainer of researchers, a source of results that are published rather than held, and a check on claims made by the companies that recruit from it.
statementBuck Institute for Research on Aging. "Leadership" and "Faculty." buckinstitute.org, accessed August 2026.↩ ↩2The institute's own pages; they record its stated faculty count and officer roster, not an independent census.
reportProPublica Nonprofit Explorer. "Buck Institute for Research on Aging," IRS Form 990 filings through fiscal year ending June 2025.↩ ↩2The figures are the institute's own filings to the IRS, republished by ProPublica; the fiscal 2025 return reports $57.2 million in revenue and $62.9 million in expenses.
paperCoppé, J.-P., Patil, C.K., Rodier, F. et al. "Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor." PLoS Biology, 2008.↩The secretory phenotype was characterised in cultured cells; its role in aged tissue was inferred from later work.
paperCampisi, J. "Aging, Cellular Senescence, and Cancer." Annual Review of Physiology, 2013. ↩
paperBaker, D.J. et al. "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders." Nature, 2011.↩The mice were a progeroid strain carrying a transgene that let p16-positive cells be killed on demand, not normally aged animals.